Pharmacyclics Articles
Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data
9 April 2013
Pharmacyclics gets second $50 million milestone from Janssen
21 August 2012
Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication
19 February 2012
Highlights of ASH meeting
13 December 2011
J&J to pay nearly $1 billion for cancer drug candidate
9 December 2011
Pharmacyclics announces management reshuffle
28 May 2009
Pharmacyclics names Ahmed Hamdy as CMO
23 March 2009
Pharmacyclics files Xcytrin with US FDA
30 April 2007
Pharmacyclics to file Xcytrin "over protest"
16 April 2007
US FDA says Pharmacyclics
26 February 2007
Pooled analysis of Xcytrin in lung cancer brain metastases
27 November 2006
Pharmacyclics secures $20M equity funding
28 August 2006
Research sheds light on Pharmacyclics' Xcytrin
16 May 2005
Pharmacyclics initiates Ph II Xcytrin trial
12 July 2004
Pharmacyclics prices $36.2 million offering
12 April 2004
Xcytrin gets FDA fast-track status
8 December 2003
FDA says OK to pivotal trial of Pharmacyclics' Xcytrin
13 January 2003
Pharmacyclics to start new trial of Xcytrin
22 April 2002
Pharmacyclics' Antrin for photoangioplasty
1 April 2002
Pharmacyclics drug treats brain metastases
14 January 2002
Pharmacyclics' Antrin well-tolerated
6 September 2001
Pharmacyclics' brain cancer drug in Ph II
11 April 2001
Pharmacyclics begins Ph I Xcytrin evaluation
29 November 1999
Pharmacyclics to raise $83.6 million
27 September 1999
QLT's shares boosted on Photofrin approval
21 July 1999
Pharmacyclics Tests Gd-Tex Photosensitizer In Phase III
28 September 1998
Stock Commentary New York
12 August 1998
Pharmacyclics Completes Patient Enrollment
12 March 1998
Stock Commentary New York
19 February 1998
Gd-Tex Radiosensitizer
30 May 1997
New York Stock Comment
19 May 1997
Pharmacyclics' Gadolite Approved In UK
23 December 1996
Pharmacyclics To Offer 2 Million Shares
24 June 1996
Pharmacyclics Announce Lu-Tex Phase I Results
24 June 1996
- Lu-Tex Photosensitizer Phase I Trial Expanded
22 April 1996
Important Developments For US Biotechnology Cos
19 February 1996
Pharmacyclics' Radiation Sensitizer
5 February 1996
Gadolite Deal For Burroughs Wellcome
3 April 1995
Pharmacyclics To File NDA For Gadolite
20 March 1995
Pharmacyclics Ph III Trial For MRI Agent
3 October 1994
Pharmacyclics' Ribozyme Analog For MDR Reversal
22 August 1994
Showing 1-56 of 56 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
